POS1062 THERAPEUTIC POTENTIAL OF IMVOTAMAB, A CD20-TARGETED BISPECIFIC IGM T CELL ENGAGER, FOR THE TREATMENT OF REFRACTORY AUTOIMMUNE DISEASE PATIENTSRacquel Domingo-Gonzalez, M. Harler, Albert F. Candia et al.|Annals of the Rheumatic Diseases|2024Cited by 9
Abstract 4179: High valency of IGM-2323, a CD20xCD3 IgM bispecific T cell engager, displaces rituximab binding and induces potent B lymphoma cell killingKevin C. Hart, Maya F. Kotturi, Kathryn Logronio et al.|Cancer Research|2022Cited by 1
Abstract 4120: Depletion of tissue-resident B cells by a CD20xCD3 IgM bispecific T cell engager in cynomolgus monkeys demonstrates effective tissue penetration and potent target cell killingMiho Oyasu, Maya F. Kotturi, Angus M. Sinclair et al.|Cancer Research|2023Cited by 0
P815: HIGH VALENCY OF IGM-2644, A CD38XCD3 IGM BISPECIFIC T CELL ENGAGER, DISPLACES DARATUMUMAB BINDING AND INDUCES POTENT MULTIPLE MYELOMA CELL KILLINGKevin C. Hart, Maya F. Kotturi, Daniel Santos et al.|HemaSphere|2023Cited by 0